secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2026-07-07T12:54:20+00:00
Accession:  0001493152-26-032263
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity Technologies reports Q2 2026 CyPath Lung sales up >200% YoY, record quarter
--------------------------------------------------------------------------------

- Q2 2026 CyPath Lung sales volume >200% YoY and >30% over Q1 2026.
- Nearly 3,000 tests performed since commercial launch.
- 155% increase in physician offices ordering CyPath Lung vs Q2 2025.
- Company expects to report Q2 2026 financial results in August.
- Initiatives include longitudinal study, oncology expansion, asthma/COPD tests.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226032263/0001493152-26-032263-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226032263/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-032263

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer